Translating Microbiome Research: from academia to industry
Starting a biotechnology company is not a simple undertaking. Translating scientific research into industrial applications present many risks and can be costly. From opioid-induced constipation to depression, the human microbiome is implicated in a wide range of health conditions. Given this, it is no wonder that the space is full of exciting biotechs developing microbiome-based interventions. With 92% of phase 1 drug-candidates failing to reach approval, it raises the question: how do you successfully translate research into a market-approved product?
In the nascent field of microbiome-based medicinal products, identifying an effective strategy for translating research into approved medicines is difficult. Many candidates have failed in the clinic and there are only a handful of market-approved drugs. Thus, to de-risk the drug development process, it is vital to consult experts.
Esteemed speakers discussing this subject matter include:
Luis Gosálbez Managing Director, Sandwalk Bioventures
Drawing on his extensive experience in the microbiome field Luis will explore what makes for a successful microbiome biotech by analysing recent failures. From Kaleido to Finch Therapeutics, stories of microbiome lay-offs or downsizing have been frequent. But whilst some companies have struggled others have soared. Luis will be describing the factors underpinning this difference, so you can avoid costly product development mistakes.
Hervé Ansanay Business Development Group Leader, Réseau SATT
The SATT Network comprises 13 technology transfer acceleration companies in France. Having created 650 start-ups, SATTs are experts at translating ideas to industry. Hervé, their business development group leader, will explain the considerations for spinning out into a biotech. This talk will be of great benefit to any entrepreneur or scientist looking to enter the biotech space.
Georges Rawadi Chief Biotech Studio, eureKARE
Georges will bring his 25 years of experience across the pharmaceutical and biotech industry to chair the event’s “Translational Microbiome” panel. He will cover the challenges encountered when going from benchtop to bedside, such as choosing the right partners for manufacturing.
Innovation Showcase: a platform for cutting-edge microbiome developers
Another key challenge when translating from academia to industry is funding. Without investment the important work being done by early-stage biotechs cannot progress. To assist with overcoming this barrier, the Pharmabiotics Conference is committed to showcasing up-and-coming researchers and biotechs, and to help promote their platforms.
As part of our innovation showcase 6 developers will take to the stage to present their ground-breaking research to our audience. Modalities of this year’s participants include phages, genetically modified bacteria, and consortia-based products.
Drug developers joining our innovation showcase include representatives from:
Quadram Institute Biosciences
Suri Biotech
CC Biotech
Concerto Biosciences
Proteon Pharmaceuticals
Novo Nordisk Foundation Centre for Biosustainability
Hear all of these presentations in person by registering for your ticket HERE
